News Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Market Closed - Japan Exchange Other stock markets 02:34:42 2024-04-19 am EDT			5-day change	1st Jan Change
1,450 ^JPY	-4.04%		-7.05%	+2.04%

Apr. 18	Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	MT
Apr. 17	Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	Apr. 17	MT
Nxera Pharma: Notice of Issuance of New Shares Under the Restricted Stock Unit (RSU) Plan and Determination of Payment Amount and Other Matters of Issuance of New Shares Under Previous Years’ RSU Plan	Apr. 17	AQ
Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	Apr. 16	MT
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	Apr. 16	AQ
Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	Apr. 16	CI
Nxera Pharma Partners with Handok c. to Distribute PIVLAZ in South Korea,	Apr. 15	MT
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for PIVLAZ™ in South Korea	Apr. 14	AQ
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	Apr. 14	CI
Nxera Pharma joins the World Orphan Drug Alliance	Apr. 08	AQ
Nxera Pharma Appoints Experienced Senior Strategy Consultant Patrick Branch as Head of Business Development for Japan and APAC	Apr. 03	AQ
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC	Apr. 03	CI
Sosei Group Corporation will Change its Name to Nxera Pharma Co., Ltd	Apr. 01	CI
Nxera Pharma is the New Name for Sosei Group	Mar. 31	AQ
Sosei Shareholders Greenlight Name Change, Top Management Appointments	Mar. 28	MT
Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma	Mar. 27	AQ
Transcript : Sosei Group Corporation - Shareholder/Analyst Call	Mar. 26
Sosei Heptares Begins Phase 1 Trial for Novel Inflammatory Bowel Disease Treatment	Mar. 21	MT
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease	Mar. 20	AQ
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	Mar. 20	AQ
Sosei Group Corporation Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	Mar. 20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Summary

Filters